Neoadjuvant Immunotherapy.png

Thursday, Oct. 8, 2026 | 11 a.m.–3 p.m. ET
Live via Zoom Webinar

Register Now

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of neoadjuvant immunotherapy. FREE for healthcare professionals, students, patients and patient advocates.

The 2026 SITC Advances in Cancer Immunotherapy Series is supported, in part, through medical education grants from
AstraZeneca Pharmaceuticals, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation. 

Program Organizers

David Carbone, MD, PhD

David Carbone, MD, PhD
The Ohio State University

Benjamin L. Maughan, MD, PharmD

Benjamin Maughan, MD, PharmD
Mays Cancer Center at University of Texas San Antonio

Sapna Patel, MD

Sapna Patel, MD
University of Colorado

Program Agenda

11–11:05 a.m.

 

Welcome

11:05–11:25 a.m.

 
State of the Art in Practice: Lung Cancer
Dwight Owen, MD, MS – The Ohio State University

11:25 a.m.–11:45 p.m.

  
State of the Art in Practice: GU and Kidney Cancer

11:45 a.m.–12:05 p.m.

 
State of the Art in Practice: Breast Cancer

12:05–12:25 p.m.

 
State of the Art in Practice: Melanoma and Non-Melanoma Skin Cancers

12:25–12:45 p.m.

 

State of the Art in Practice: GI Cancers, MSI-High Colon Cancer

12:45–1:05 p.m.

 
State of the Art in Practice: Head and Neck Cancers

1:05–1:20 p.m.

 

Break

1:20–1:40 p.m.

 

Cancer Immunotherapy in Practice – Surgical Issues Associated with Neoadjuvant Immunotherapy, Adoption into the Community

1:40–2 p.m.

 

Cancer Immunotherapy in Practice – Defining the Contribution of Each Phase

2–3 p.m.

 

Faculty Panel

3 p.m.

 

Closing Remarks

SITC ACI Series

This program is part of the SITC ACI series. View below to explore more programs in the 2026 ACI series.

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to onlineeducation@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches for neoadjuvant treatment of early-stage disease.

  • Summarize recent updates in neoadjuvant immunotherapy for early-stage cancers including potential risks, toxicities, and toxicity management.

  • Implement neoadjuvant immunotherapy for early-stage cancers into clinical practice appropriately.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer (SITC).  Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

ABIM_Logo.jpgSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

Partners designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Partners designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

Disclosure of Conflicts of Interest

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

The 2026 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the Advanced Practitioner Society for Hematology and Oncology and the Association of Cancer Care Centers.

Partners for Advancing Clinical Education Logo

The 2026 ACI series is jointly provided by Partners for Advancing Clinical Education (Partners) and the Society for Immunotherapy of Cancer.